Repositioning proton pump inhibitors as anticancer drugs by targeting the thioesterase domain of human fatty acid synthase

Valerie E. Fako, Xi Wu, Beth Pflug, Jing Yuan Liu, Jian-Ting Zhang

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Fatty acid synthase (FASN), the enzyme responsible for de novo synthesis of free fatty acids, is up-regulated in many cancers. FASN is essential for cancer cell survival and contributes to drug resistance and poor prognosis. However, it is not expressed in most nonlipogenic normal tissues. Thus, FASN is a desirable target for drug discovery. Although different FASN inhibitors have been identified, none has successfully moved into clinical use. In this study, using in silico screening of an FDA-approved drug database, we identified proton pump inhibitors (PPIs) as effective inhibitors of the thioesterase activity of human FASN. Further investigation showed that PPIs inhibited proliferation and induced apoptosis of cancer cells. Supplementation of palmitate, the end product of FASN catalysis, rescued cancer cells from PPI-induced cell death. These findings provide new evidence for the mechanism by which this FDA-approved class of compounds may be acting on cancer cells.

Original languageEnglish (US)
Pages (from-to)778-784
Number of pages7
JournalJournal of Medicinal Chemistry
Volume58
Issue number2
DOIs
StatePublished - Jan 22 2015

Fingerprint

Fatty Acid Synthases
Proton Pump Inhibitors
Drug Delivery Systems
Neoplasms
Pharmaceutical Databases
Palmitates
Drug Discovery
Catalysis
Nonesterified Fatty Acids
Drug Resistance
Computer Simulation
Cell Survival
Cell Death
human FASN protein
Apoptosis
Enzymes

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Repositioning proton pump inhibitors as anticancer drugs by targeting the thioesterase domain of human fatty acid synthase. / Fako, Valerie E.; Wu, Xi; Pflug, Beth; Liu, Jing Yuan; Zhang, Jian-Ting.

In: Journal of Medicinal Chemistry, Vol. 58, No. 2, 22.01.2015, p. 778-784.

Research output: Contribution to journalArticle

@article{ffb1f827f7cd438f8512cbb7cfaf09c9,
title = "Repositioning proton pump inhibitors as anticancer drugs by targeting the thioesterase domain of human fatty acid synthase",
abstract = "Fatty acid synthase (FASN), the enzyme responsible for de novo synthesis of free fatty acids, is up-regulated in many cancers. FASN is essential for cancer cell survival and contributes to drug resistance and poor prognosis. However, it is not expressed in most nonlipogenic normal tissues. Thus, FASN is a desirable target for drug discovery. Although different FASN inhibitors have been identified, none has successfully moved into clinical use. In this study, using in silico screening of an FDA-approved drug database, we identified proton pump inhibitors (PPIs) as effective inhibitors of the thioesterase activity of human FASN. Further investigation showed that PPIs inhibited proliferation and induced apoptosis of cancer cells. Supplementation of palmitate, the end product of FASN catalysis, rescued cancer cells from PPI-induced cell death. These findings provide new evidence for the mechanism by which this FDA-approved class of compounds may be acting on cancer cells.",
author = "Fako, {Valerie E.} and Xi Wu and Beth Pflug and Liu, {Jing Yuan} and Jian-Ting Zhang",
year = "2015",
month = "1",
day = "22",
doi = "10.1021/jm501543u",
language = "English (US)",
volume = "58",
pages = "778--784",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "2",

}

TY - JOUR

T1 - Repositioning proton pump inhibitors as anticancer drugs by targeting the thioesterase domain of human fatty acid synthase

AU - Fako, Valerie E.

AU - Wu, Xi

AU - Pflug, Beth

AU - Liu, Jing Yuan

AU - Zhang, Jian-Ting

PY - 2015/1/22

Y1 - 2015/1/22

N2 - Fatty acid synthase (FASN), the enzyme responsible for de novo synthesis of free fatty acids, is up-regulated in many cancers. FASN is essential for cancer cell survival and contributes to drug resistance and poor prognosis. However, it is not expressed in most nonlipogenic normal tissues. Thus, FASN is a desirable target for drug discovery. Although different FASN inhibitors have been identified, none has successfully moved into clinical use. In this study, using in silico screening of an FDA-approved drug database, we identified proton pump inhibitors (PPIs) as effective inhibitors of the thioesterase activity of human FASN. Further investigation showed that PPIs inhibited proliferation and induced apoptosis of cancer cells. Supplementation of palmitate, the end product of FASN catalysis, rescued cancer cells from PPI-induced cell death. These findings provide new evidence for the mechanism by which this FDA-approved class of compounds may be acting on cancer cells.

AB - Fatty acid synthase (FASN), the enzyme responsible for de novo synthesis of free fatty acids, is up-regulated in many cancers. FASN is essential for cancer cell survival and contributes to drug resistance and poor prognosis. However, it is not expressed in most nonlipogenic normal tissues. Thus, FASN is a desirable target for drug discovery. Although different FASN inhibitors have been identified, none has successfully moved into clinical use. In this study, using in silico screening of an FDA-approved drug database, we identified proton pump inhibitors (PPIs) as effective inhibitors of the thioesterase activity of human FASN. Further investigation showed that PPIs inhibited proliferation and induced apoptosis of cancer cells. Supplementation of palmitate, the end product of FASN catalysis, rescued cancer cells from PPI-induced cell death. These findings provide new evidence for the mechanism by which this FDA-approved class of compounds may be acting on cancer cells.

UR - http://www.scopus.com/inward/record.url?scp=84921473930&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921473930&partnerID=8YFLogxK

U2 - 10.1021/jm501543u

DO - 10.1021/jm501543u

M3 - Article

C2 - 25513712

AN - SCOPUS:84921473930

VL - 58

SP - 778

EP - 784

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 2

ER -